Drug Profile
CART 30 - AbelZeta Pharma
Alternative Names: Anti-CD30 CART cells; Anti-CD30 chimeric antigen receptor T cell therapy - AbelZeta Pharma; CD30 specific CART cellsLatest Information Update: 27 Nov 2023
Price :
$50
*
At a glance
- Originator Chinese PLA General Hospital
- Class CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies; Vaccines
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Hodgkin's disease; Non-Hodgkin's lymphoma